Form 4: Xtant CEO Granted DSUs and Performance Units

Xtant Medical CEO Sean Browne received 394,937 DSUs and up to 789,874 PSUs tied to a three-year stock performance period, with vesting through 2029.

Summary

• President and CEO (and Director) Sean E. Browne acquired 394,937 shares at $0, representing a Deferred Stock Unit (DSU) award granted on 2025-11-15 under the Amended and Restated 2023 Equity Incentive Plan.
• DSU vesting schedule: 98,734 shares on each of 2026-11-15, 2027-11-15, and 2028-11-15, and 98,735 shares on 2029-11-05; settlement of vested shares is deferred per the DSU agreement.
• Following the transaction, beneficial ownership stands at 2,575,274 shares, including 1,213,677 shares issuable upon vesting/settlement of RSUs or DSUs.
• Performance Stock Units (PSUs) granted on 2025-11-15 with a maximum of 789,874 shares (200% of the 394,937 target) at $0, expiring 2028-11-15.
• PSUs vest in one-third increments based on specified stock price performance goals during a three-year performance period and require continued service.
• Attorney-in-fact signature dated 2025-11-18.

Sentiment

Score: 6

Explanation: Governance-positive, performance-based equity design aligns incentives, but sizeable potential share issuance introduces dilution risk.

Positives

• Equity awards are performance- and service-based (PSUs tied to stock price goals over three years), aligning executive incentives with shareholder outcomes.
• Clear vesting schedule provides transparency: DSUs vest annually through 2028 with a final tranche on 2029-11-05.
• No cash consideration ($0 price) for awards, preserving cash while focusing on long-term equity alignment.
• Beneficial ownership totals 2,575,274 shares, signaling material executive exposure to equity value; includes 1,213,677 unvested RSU/DSU shares.

Negatives

• Potential future share issuance from DSUs and PSUs could be dilutive if fully vested and, for PSUs, if performance goals are achieved (maximum PSU payout of 789,874 shares).
• Long vesting horizon (to 2029 for DSUs) delays alignment of realized compensation with near-term company performance.
• PSU structure based solely on stock price performance goals may emphasize market factors over operating metrics.

Future Outlook

Equity awards vest over a three-year performance period (PSUs) and multi-year service schedule (DSUs). Up to 200% of target PSU shares may be earned if specified stock price goals are achieved, with continued employment required.

Industry Context

Performance-based equity (PSUs) with three-year performance periods and multi-year time-based DSUs are common in medtech and broader healthcare device sectors to align pay with shareholder returns while conserving cash.

Comparison to Industry Standards

• Three-year PSU performance periods with a 200% maximum payout are typical among medtech peers such as Globus Medical, Orthofix, and Integra Lifesciences.
• Time-based vesting over 3–4 years for DSU/RSU awards aligns with standard U.S. executive compensation practices across medical device companies.
• Use of stock price performance goals (rather than earnings or revenue metrics) is a common but debated practice; many peers blend TSR/price hurdles with financial KPIs.

Related Party Transactions

• Grant to President and CEO Sean E. Browne of 394,937 DSUs (reported as common stock acquired at $0) under the Amended and Restated 2023 Equity Incentive Plan.
• Grant of PSUs with a target of 394,937 shares and a maximum of 789,874 shares (200% of target), vesting based on stock price performance goals over three years and subject to service.

Stakeholder Impact

• Shareholders: Potential dilution if DSUs and PSUs vest, particularly at the PSU maximum (789,874 shares).
• Employees/Management: Strong incentive alignment via performance- and time-based equity encouraging retention and long-term value creation.
• Creditors: No near-term cash impact from awards, preserving liquidity.

Next Steps

• Potential PSU vesting in one-third increments over the three-year performance period if stock price goals are met and service conditions satisfied.
• DSU tranches vest on scheduled dates through 2029; settlement occurs later per the DSU agreement.

Key Dates

Keywords

Xtant Medical, XTNT, insider transaction, Form 4, Sean Browne, DSU, PSU, equity incentive plan, stock-based compensation, beneficial ownership